- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Facing pharmacy trends for the remainder of the year
- Good Neighbor pharmacists can vaccinate patients under collaborative-practice agreements
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
SAN DIEGO Drug maker Somaxon Pharmaceuticals has made its treatment for insomnia available by prescription, the company said Tuesday.
Somaxon announced the availability of Silenor (doxepin), which received approval from the Food and Drug Administration in March as a treatment for insomnia characterized by difficulty with sleep maintenance.
“The commercial availability of Silenor, the first and only prescription product approved for the treatment of sleep maintenance insomnia that is not a controlled substance, is an important milestone for Somaxon and marks the completion of our product launch preparations,” Somaxon president and CEO Richard Pascoe said.
The company will promote the drug to healthcare providers along with Procter & Gamble.